Benzinga | Apr 12, 2021 04:01PM EDT

Celcuity Highlights PResentation Of Results From Gedatolisib Studies At AACR Annual Meeting

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for treating patients with cancer, presented results of studies evaluating gedatolisib (a pan-PI3K/mTOR inhibitor), inavolisib (a PI3K-? inhibitor), and navitoclax (a BCL inhibitor) in breast and ovarian patient tumors. Results were presented in two e-posters at the American Association for Cancer Research (AACR) Annual Meeting.